Propanc Biopharma (PPCB) Preferred Stock Liabilities (2025)
Propanc Biopharma (PPCB) posted quarterly Preferred Stock Liabilities of $1.0 million for Q4 2025, up 147.59% quarter-over-quarter from $403892.0 in Q2 2025.
Propanc Biopharma (PPCB) Preferred Stock Liabilities (2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Preferred Stock Liabilities for 1 consecutive years, with $1.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Preferred Stock Liabilities changed N/A year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (changed N/A YoY), while the FY2025 annual figure was $403892.0, changed N/A from the prior year.
- Preferred Stock Liabilities improved to $1.0 million in Q4 2025 per PPCB's latest filing, from $403892.0 in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $1.0 million in Q4 2025 and bottomed at $403892.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Mn |
| Jun 30, 2025 | 403,892.00 |